(Q78156195)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10456658%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

title

Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10456658%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

1 reference

phase II clinical trial

1 reference

Primary systemic amyloidosis

inferred from title

1 reference

1

M A Gertz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10456658%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

3

J A Lust

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10456658%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

2

M Q Lacy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10456658%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

author name string

P R Greipp

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10456658%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

T E Witzig

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10456658%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

R A Kyle

series ordinal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10456658%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

publication date

1 July 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10456658%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10456658%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10456658%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10456658%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

page(s)

104-109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10456658%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf02785843

11 December 2019

exact match

0 references

cites work

High-dose dexamethasone for refractory or relapsing multiple myeloma

1 reference

12 December 2020

Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

1 reference

12 December 2020

Inhibitor of the thrombin time in systemic amyloidosis: a common coagulation abnormality

1 reference

12 December 2020

Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes

1 reference

12 December 2020

Phase II trial of alpha-tocopherol (vitamin E) in the treatment of primary systemic amyloidosis

1 reference

12 December 2020

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

1 reference

12 December 2020

Amyloidosis: prognosis and treatment

1 reference

12 December 2020

Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases

1 reference

12 December 2020

Biology and therapy of immunoglobulin deposition diseases

1 reference

12 December 2020

Amyloidosis (AL). Clinical and laboratory features in 229 cases

1 reference

12 December 2020

Classification of amyloidosis by the detection of clonal excess of plasma cells in the bone marrow

1 reference

12 December 2020

The classification of amyloid deposits in clinicopathological practice

1 reference

12 December 2020

Beta 2-microglobulin predicts survival in primary systemic amyloidosis

1 reference

12 December 2020

High-dose glucocorticoid treatment of resistant myeloma

1 reference

12 December 2020

[Lack of therapeutic effect on primary amyloidosis by interferon-alpha].

1 reference

12 December 2020

Interferon plus glucocorticoids as intensified maintenance therapy prolongs tumor control in relapsed myeloma

1 reference

12 December 2020

[Role of glucocorticoids in the treatment of multiple myeloma]

1 reference

12 December 2020

Current concepts on the pathogenesis of systemic amyloidosis

1 reference

12 December 2020

Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors

1 reference

12 December 2020

[Difficulties in the therapy of primary amyloidosis].

1 reference

12 December 2020

Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945.

1 reference

12 December 2020

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

1 reference

12 December 2020

Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: synergy through modulation of interleukin-6 autocrine loop at multiple sites.

1 reference

12 December 2020

Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine

1 reference

12 December 2020

Combination of interferon and dexamethasone in refractory multiple myeloma

1 reference

12 December 2020

Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival

1 reference

12 December 2020

New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin

1 reference

12 December 2020

Phase II trial of recombinant interferon alfa-2 in the treatment of primary systemic amyloidosis

1 reference

12 December 2020

Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.

1 reference

12 December 2020

Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies

1 reference

12 December 2020

Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis

1 reference

12 December 2020

[Rapid progression of systemic amyloidosis after high-dose corticosteroid therapy in multiple myeloma]

1 reference

12 December 2020

Response rates and survival in primary systemic amyloidosis

1 reference

12 December 2020

Treatment of AL-amyloidosis with dexamethasone plus alpha interferon

1 reference

12 December 2020

Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome

1 reference

12 December 2020

Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989

1 reference

12 December 2020

Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines

1 reference

12 December 2020

Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo

1 reference

12 December 2020

Treatment of primary amyloidosis.

1 reference

12 December 2020

Diagnosis and treatment of amyloidosis

1 reference

12 December 2020

Primary dexamethasone treatment of multiple myeloma

1 reference

12 December 2020

Patterns of amyloidosis and their association with plasma-cell dyscrasia, monoclonal immunoglobulins and Bence-Jones proteins

1 reference

12 December 2020

Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma

1 reference

12 December 2020

Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02785843

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10456658%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

11 December 2019

0 references

1 reference